Small vessels, dementia and chronic diseases - molecular mechanisms and pathophysiology by Horsburgh, Karen et al.
                          Horsburgh, K., Wardlaw, J. M., van Agtmael, T., Allan, S. M., Ashford, M.
L. J., Bath, P. M., ... Work, L. M. (2018). Small vessels, dementia and
chronic diseases - molecular mechanisms and pathophysiology. Clinical
Science, 132(8), 851-868. https://doi.org/10.1042/CS20171620
Peer reviewed version
Link to published version (if available):
10.1042/CS20171620
Link to publication record in Explore Bristol Research
PDF-document
This is the author accepted manuscript (AAM). The final published version (version of record) is available online
via Portland Press at http://www.clinsci.org/content/132/8/851.article-info. Please refer to any applicable terms of
use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
 1 
 
 
‘Small vessels, dementia and chronic diseases – 
molecular mechanisms and pathophysiology’ 
Workshop proceedings, Jan 25-26th 2017 
 
 
 
1. Karen Horsburgh, Centre for Discovery Brain Sciences, University of Edinburgh 
2. Joanna Wardlaw, Centre for Clinical Brain Sciences, Dementia Research Institute, University of Edinburgh 
3. Tom van Agtmael,  Institute of Cardiovascular and Medical Sciences, University of Glasgow 
4. Stuart Allan, Faculty of Biology, Medicine and Health, University of Manchester 
5. Mike Ashford, School of Medicine, University of Dundee 
6. Philip M Bath, Stroke Trials Unit, Division of Clinical Neuroscience, University of Nottingham 
7. Rosalind Brown,  Centre for Clinical Brain Sciences, University of Edinburgh 
8. Jason Berwick, Department of Psychology The University of Sheffield   
9. M. Zameel Cader, Nuffield Department of Clinical Neurosciences, University of Oxford 
10. Roxana O Carare, Faculty of Medicine, University of Southampton  
11. John B Davies, Alzheimer’s Research UK Oxford Drug Discovery Institute,  University of Oxford 
12. Jessica Duncombe, Centre for Discovery Brain Sciences, University of Edinburgh 
13. Tracy D Farr, School of Life Sciences, Nottingham University  
14. Jill Fowler, Centre for Discovery Brain Sciences, University of Edinburgh 
15. Jozien Goense, Institute of Neuroscience and Psychology,  University of Glasgow 
16. Alessandra Granata, Department of Clinical Neurosciences, University of Cambridge 
17. Catherine Hall, School of Psychology, University of Sussex 
18. Atticus Hainsworth, Molecular and Clinical Sciences Research Institute, St Georges University of London  
19. Adam Harvey,  Institute of Cardiovascular and Medical Sciences, University of Glasgow 
20. Cheryl Hawkes, Faculty of Science, Technology, Engineering & Mathematics, Open University 
21. Anna Joutel, Genetics and Pathogenesis of Cerebrovascular Diseases, INSERM, Université Paris Diderot-
Paris 7,  Paris, France. 
22. Rajesh Kalaria, Institute of Neuroscience Newcastle University 
23. Patrick G. Kehoe,  Bristol Medical School, , University of Bristol 
24. Catherine Lawrence, Faculty of Biology, Medicine and Health, University of Manchester 
25. Andy Lockhart, GSK (currently  Heptares Therapeutics) 
26. Seth Love, Clinical Neurosciences, University of Bristol 
 2 
 
27. Malcolm Macleod, Centre for Clinical Brain Sciences, University of Edinburgh 
28. Mhairi Macrae, Institute of Neuroscience and Psychology,  University of Glasgow 
29.  Hugh Stephen Markus, Department of Clinical Neurosciences, University of Cambridge 
30. Chris McCabe, Institute of Neuroscience and Psychology,  University of Glasgow 
31. Barry W McColl, The Roslin Institute & R(D)SVS, UK Dementia Research Institute, University of Edinburgh 
32. Paul James Meakin, Division of Molecular & Clinical Medicine, School of Medicine,University of Dundee 
33. Alyson Miller, Institute of Cardiovascular and Medical Sciences, University of Glasgow 
34. Maiken Nedergaard, University of Rochester Medical Center and University of Copenhagen's Center of Basic 
and Translational Neuroscience. 
35. Michael O'Sullivan, Mater Centre for Neuroscience and Queensland Brain Institute, Brisbane, Australia 
36. Terry Quinn, Institute of Cardiovascular and Medical Sciences, University of Glasgow 
37. Rikesh Rajani, Genetics and Pathogenesis of Cerebrovascular Diseases, INSERM, , Université Paris Diderot-
Paris 7,  Paris, France. 
38. Lisa Saksida, Robarts Research Institute, Western University, London, Ontario 
39. Colin Smith, Centre for Clinical Brain Sciences, University of Edinburgh 
40. Kenneth J.  Smith, Department of Neuroinflammation, UCL Institute of Neurology, London 
41. Rhian Touyz, Institute of Cardiovascular and Medical Sciences, University of Glasgow 
42. Rebecca C. Trueman, School of Life Sciences, Nottingham University 
43. Tao Wang, Faculty of Biology, Medicine and Health,  University of Manchester 
44. Anna Williams, MRC Centre for Regenerative Medicine, University of Edinburgh 
45. Steve Williams, Institute of Psychiatry, Kings  College London 
46. Lorraine Work, Institute of Cardiovascular and Medical Sciences, University of Glasgow 
 
 
 
  
 3 
 
INTRODUCTION 
 
Cerebral small vessel disease (SVD) is a major health challenge. Therapeutic approaches remain limited, hampered 
by the lack of mechanistic understanding and identification of therapeutic targets. Relevant animal models could 
provide a cornerstone to basic scientific studies of disease mechanisms and pre-clinical studies of potential therapies, 
but there is a critical need to improve the current translational gap that exists between pre-clinical research and 
treatments in patients. The Medical Research Council Dementias Platform UK (MRC DPUK) Vascular Experimental 
Medicine Theme identified that a comprehensive assessment of the latest developments in animal models and of their 
contribution to understanding of cerebral microvascular disease would reduce the translational gap. In response to 
this, a two day workshop took place in late January 2017 at the British Heart Foundation Centre of Research 
Excellence in Glasgow, Scotland in conjunction with MRC DPUK and brought together experts from several 
disciplines in cerebrovascular disease, dementia and cardiovascular biology, to highlight current advances in these 
fields, explore synergies and scope for development. There were presentations from UK and international researchers 
and a specific focus on animal models of cerebral microvascular disease and dementia, considering vascular biology, 
neurogliovascular coupling, blood-brain barrier function, neuroinflammation, cerebral drainage pathways, and 
methodological and translational challenges (see Figure 1 for the general organisation of the meeting including the 
key topics and themes discussed). This overview provides a summary of the key talks, with a particular focus on 
mechanisms of cerebral vascular disease (see Figure 2) and improving translation. These talks were followed by 
related themed discussion groups on the gaps in knowledge and requirements to advance knowledge, the outcomes 
of which are highlighted in Table 1.  Additional related articles are published in the Special Edition of Clinical Science 
(http://www.portlandpresspublishing.com/cc/small-vessels). 
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Figure 1 General organisation of the meeting 
 
 
 
 
 
 
CEREBRAL VASCULAR DISEASE: CLINICAL CONTEXT     
 
Of the approximate 17 million strokes per year worldwide, 20-25% are due to small vessel disease (SVD). 
Additionally, a large burden of silent SVD contributes to up to 45% of the 35-42 million new cases of dementia globally 
each year.  SVD is difficult to research, small vessel stroke being neglected in stroke research, and vascular causes 
are neglected in dementia research. Human pathology often reflects late disease stages with few relevant 
experimental models identified [1,2] Consequently, treatment is empirical and probably suboptimal.  The individual 
SVD features on neuroimaging are now well-described with standardised terminology [3]. These include acute 
(recent) small subcortical infarcts and clinically covert features (lacunes, white matter hyperintensities (WMH), 
microbleeds, perivascular spaces, microinfarcts, and cerebral atrophy), and many haemorrhagic strokes.  From early 
neuropathology studies onwards, SVD has been the vascular lesion most strongly associated with vascular cognitive 
impairment (VCI) [4], an observation confirmed consistently through more recent large cohort studies of donated brain 
tissue, showing that neuropathological SVD is associated with cognitive impairment [5]  
SVD features are associated with age and several vascular risk factors (hypertension, smoking, diabetes, 
hypercholesterolemia), but vascular risk factors explain only a small proportion of the variance [6] leaving a large 
Introduction and background to 
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• White matter, inflammation and hypoxia
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proportion unexplained. Potential pathophysiological mechanisms include vessel stiffening, blood brain barrier failure, 
poorer premorbid white matter integrity [7,8] a cross-sectional association with reduced cerebral blood flow [9,10], and 
several underlying genetic contributors [11].  
Progress in reducing SVD requires questioning of conventional wisdom. Firstly, the effects of SVD on the brain are 
both diffuse and more dynamic than appreciated previously [12,13]. Subcortical lesions have remote effects; lesions 
can appear silently or cause symptoms, or can resolve completely, cavitate, or form a WMH [14]. WMH, lacunes and 
microbleeds may increase, but also decrease [15,16] which suggests that these lesions do not indicate permanent 
brain damage only. Perivascular spaces are crucial for cerebral interstitial fluid drainage and waste clearance 
[17].They are a site of inflammation and amyloid protein build-up, linking to Alzheimer’s disease. Other cell types and 
structures are involved in SVD, not just the vascular endothelium  and smooth muscle cells, but also microglia, 
astrocytes, oligodendrocytes, pericytes, matrix proteins all play a role. Finally, data from humans and experimental 
models (see below) indicate a vulnerability to SVD in part [18]  explaining why vascular risk factor exposure in some 
people is far more devastating than in others.  
 
 
 
CEREBRAL VASCULAR DISEASE:  RODENT MODELS      
 
 Whilst there is no one model that captures the complexities of SVD and VCI, different animal models have 
been studied that encompass many hypothesised causes (e.g. SVD); hypoxic hypoperfusion injury secondary to large 
artery disease; or genetic influences (see recent review [2] and previous systematic review [19]).  
A widely studied model is the spontaneously hypertensive stroke prone (SHRSP) rat which develops malignant 
hypertension. This model has been reported to develop SVD-like features including white matter changes, 
lipohyalonisis and fibrinoid necrosis [20,21]. Endothelial and the earliest measured myelin changes have also been 
shown to predate hypertension [22]. Analysis of gene and protein expression before the onset of hypertension 
highlighted several genes and proteins associated with SVD and pathways that may underlie these changes (e.g. 
matrix and vascular integrity, inflammation), and suggests a potential predisposition of SHRSPs to development of 
SVD-like pathology which is later exacerbated by hypertension [23]. However these findings vary and others have 
failed to identify white matter damage in older SHRSP in the absence of stroke [24] and in other models of 
hypertension such as an inducible transgenic model [25]. Additional factors, such as added dietary salt, hypoperfusion 
and high fat diet have been shown to exacerbate white matter pathology in SHRSP [26] similar to such factors 
accelerating human SVD.  
Alternative models of hypertension have been developed including the effects of angiotensin (ANG) administration. 
Low doses of angiotensin-II (ANGII) in rodents results in a slow-developing rise in blood pressure which impairs 
neurogliovascular (NGVU) coupling and endothelial responses before the onset of hypertension and in the absence of 
SVD like changes [27] . More recently, simultaneous administration of ANGII and L-NAME (NG-nitro-L-arginine methyl 
ester) led to chronically elevated blood pressure and produced early SVD-like features [28] . Key features relevant to 
human SVD were reported in this model including hypertrophy of the cerebral vessel wall, structural impairment of the 
NGVU, hippocampal atrophy, blood brain barrier (BBB) impairment and occasional microinfarcts and microbleeds.  
To investigate vascular insufficiency as a central mechanism in the pathophysiology of VCI, models of cerebral 
hypoperfusion were developed [29]. These models have been refined over the years to induce hypoperfusion whilst 
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avoiding severe reductions in blood flow that would cause immediate ischaemia. The recent models involve stenosis 
of the common carotid arteries which immediately restricts blood flow to the forebrain on application of microcoils [30], 
or gradually restricts blood flow by the use of constrictor devices [31]. These models have been widely studied with 
behavioural measures of cognition which demonstrate particular impairments in spatial working memory reminiscent 
of the disrupted frontal cortical circuitry found in VCI [29, 32]. In these models, reduced perfusion is thought to cause a 
slowly evolving diffuse white matter pathology that can be detected using a variety of approaches such as 
immunohistochemistry and in vivo magnetic resonance imaging (MRI).  The oxygen levels are reduced to hypoxic 
levels in white matter, which is thought to be the main driver of the ensuing pathological changes [29]. These models 
have been widely studied to understand the pathophysiology of hypoperfusion-induced white matter changes that are 
often accompanied by indices of inflammation. Carotid stenosis induced using microcoils in the mouse has also been 
shown to culminate in marked changes to microvascular structure, BBB breakdown, glio-vascular damage and 
microinfarcts/microbleeds relevant to human SVD [33]. These studies are predominantly conducted in C57Bl/6J mice 
which have poor collateral flow through the Circle of Willis and the resultant effects of microcoil/constrictor application 
assigned to reduced cerebral perfusion. However other, albeit ill-defined, effects on vascular stiffness/pulsatility and 
cerebrospinal fluid (CSF) drainage may also contribute to the pathology. In a longitudinal study in humans, there is an 
absence of a direct association between carotid stenosis and WMH or cognitive decline and instead a link with 
vascular stiffness [34].  
Notably, these models of carotid stenosis and hypertension often lack the overt white matter lesions (WML) 
characteristic of SVD. However, WML are difficult to detect pathologically and a combination of different risk factors 
may be required to produce WML. As indicated above, the effects of hypoperfusion and diet have been studied in the 
SHRSP model [26] which exacerbate white matter changes, as compared to individual factors, and precipitate overt 
WML. Models with co-morbidities may more accurately reflect clinical SVD and be considered as a basis for testing 
therapeutic interventions.  
A number of different mouse models that express highly penetrant gene mutations linked to familial SVD (NOTCH3, 
COL4A1, COL4A2, HTRA1) have provided important insights into causal pathways related to these gene mutations. 
Interestingly, investigation of these models has now indicated that these different gene mutations may lead to 
common convergent pathways involving the impairment of extracellular matrix (ECM) function [35]. Further genome 
wide association studies (GWAS) have shown common variants associated with familial SVD, such as COL4A1/4A2, 
are also risk factors for common sporadic SVD [36]. Thus, an emerging view is that these models may be useful for 
probing mechanisms important not only in rare monogenic forms of SVD, but also in the more common sporadic forms 
of SVD, opening up avenues of potential therapeutic intervention.  
Both vascular and Alzheimer's disease pathologies appear to work synergistically to promote neurodegeneration and 
cognitive impairments [37]. Further, there is considerable overlap between risk factors for cerebral microvascular 
disease, cardiovascular disease and Alzheimer’s disease, and yet the synergies between these areas are so far 
largely unexplored in models.  Animal models could provide a powerful basis to tease out molecular interactions. 
Amyloid is believed to be a key driver of the pathophysiology of AD so most work has focused on models that 
accumulate amyloid in the brain. Rodents do not naturally develop and deposit amyloid, but genetically modified mice 
were developed that harbour mutations in human amyloid precursor protein associated with familial forms of AD 
(TgAPP) and that lead to age-dependent accumulation of amyloid. The study of these TgAPP models revealed that a 
prominent cerebrovascular dysfunction occurs prior to the onset of amyloid deposition, which would be consistent with 
impaired vasoreactivity and reduced CBF seen in AD patients [37].  TgAPP models are now being probed to study 
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interactions with risk factors such as hypertension and high fat diet which in general have been shown to exacerbate 
the cerebrovascular dysfunction and progression of amyloid pathology [37,38].  
Across the various models, vascular haemodynamics and NGVU coupling are impaired [see 28] and related to 
breakdown in cell-cell communication and signalling within the NGVU and supporting ECM. Whilst animal models are 
limited in their ability to fully recapitulate human SVD, they remain pertinent to tease out specific questions that are 
impossible to address in human studies and to identify molecular targets.  
 
 
MECHANISMS RELEVANT TO CEREBRAL VASCULAR DISEASE 
 
Figure 2: Mechanisms relevant to cerebral vascular disease 
An outline of mechanisms relevant to cerebral vascular disease and VCI. These mechanisms were highlighted 
during the workshop and described in more detail in the text. In general, downstream of risk factors, a cascade of 
key events are indicated, of which some may be considered as primary events (eg endothelial changes, 
inflammation, oxidative stress) and may also be bidirectional, leading to cognitive impairment. (Abbreviations: BBB, 
blood brain barrier, MMP, matrix metalloproteinase) 
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a) Endothelial-related mechanisms  
The exact molecular and cellular mechanisms underlying cerebral microvascular disease remain elusive, but 
endothelial dysfunction seems to be especially important.  Cerebral endothelial cells regulate vascular tone and blood 
flow, protect against thrombosis, inflammation and fibrosis, control exchange across the blood-brain barrier, modulate 
innate immunity and influence clearance of amyloid peptides [39,40]. In addition, and unique to the cerebrovascular 
system, the microvascular endothelium is critically involved in blood brain function and neuroprotection, through 
autoregulatory mechanisms that protect against barotrauma. Consequences of cerebrovascular autoregulatory 
dysfunction include structural injury to capillaries, microvascular rarefaction, exaggerated disruption of the blood brain 
barrier, neuroinflammation, neurodegeneration and increased susceptibility to intracerebral haemorrhage. This link 
between impaired autoregulation and downstream microvascular injury has been demonstrated experimentally and 
clinically. 
Endothelial-cell (EC) signalling is mediated through production of numerous endothelial cell-derived vasoactive 
agents, including nitric oxide (NO), endothelium-derived hyperpolarizing factors (EDHF), endothelium-derived relaxing 
factors (EDRF), eicosanoid mediators (EETs, HETEs), prostaglandins, and endothelin-1 (ET-1) [41,42]. Endothelial-
derived NO is not only a potent vasodilator, but also inhibits platelet aggregation inflammation, apoptosis, fibrosis and 
vascular smooth muscle cell proliferation as well as modulates mitochondrial function, neuronal metabolism and 
synaptic transmission [43]. Cerebrovascular endothelial cells possess reactive oxygen species (ROS)-generating 
enzymes, such as NADPH oxidases (Nox) and mitochondrial oxidases that produce superoxide and hydrogen 
peroxide, important in redox signalling and endothelial function [44,45] . Because the endothelium is in direct contact 
with blood flow, it ‘senses’ haemodynamic changes and adapts accordingly through production of EC-derived factors, 
such as NO, EDRF and prostacyclins to induce vasodilation and prevent vascular damage or ET-1 and 20- 
hydroxyeicosatetraenoic acid to promote vasoconstriction. At the capillary level, endothelial cells are in direct contact 
with neurons via astrocytes and as such there is ‘cross-talk’ between vascular and neural cells through NGVU 
coupling, important in regulating neural activity and cerebral function [46].   
Ageing, cardiovascular disease and ischaemia/hypoxia are associated with endothelial damage that impacts 
microvascular function, moment-to-moment adjustment of regional blood flow and neuronal function [47]. Molecular 
mechanisms involved include reduced microvascular eNOS-derived NO production with consequent decline in 
cerebrovascular, neuronal, astrocyte, microglial and angiogenic function. Mitochondrial damage, production of 
arachidonic metabolites and increased oxidative stress are also important. Decreased NO bioavailability in 
microvascular endothelial cells increases expression of amyloid precursor protein (AβPP) and β-site AβPP cleaving 
enzyme 1 (BACE-1) as well as Aβ formation, suggesting a role for endothelial dysfunction in neurodegenerative 
pathologies, such as Alzheimer’s disease [48,49].  Moreover chronic reduction of NO generation and increased 
production of pro-inflammatory cytokines (TNF-α, IL-1β, interferon γ) increases endothelial permeability, 
transmigration of pro-inflammatory cells and blood brain barrier dysfunction, promoting neuroinflammatory and 
neurodegenerative processes [50,51].  
Increased ROS production in the cerebral microvasculature is due primarily to hyperactivation of Noxs (particularly 
Nox2 and Nox4) [52-54], but also to disruption of mitochondrial respiratory chain oxidases, decreased anti-oxidant 
capacity, reduced nuclear factor erythroid 2–related factor 2 (Nrf-2)  activity, uncoupled eNOS, and increased levels 
of asymmetric dimethylarginine (ADMA), an endogenous NOS inhibitor [55,56] . Vascular oxidative stress, activation 
of endothelial cell cation channels, such as transient receptor potential (TRP) melastatin 2 [57]  and TRP vanilloid 4 
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cation channels [58] , and induction of calcium  and redox-sensitive signalling pathways promote oxidative 
modification of lipids, proteins and DNA causing endothelial, pericyte and neuronal cell injury [59]. Overexpression of 
the anti-oxidant superoxide dismutase -1 rescues cerebral endothelial dysfunction associated with neurodegeneration 
[60], while resveratrol treatment improves cerebromicrovascular endothelial function, reduces Nox activity and 
rescues NVGU coupling in aged mice [61].  
 Thus, endothelium-mediated mechanisms of cerebro-microvascular dysfunction involve a complex network of 
factors and systems. There is important interplay between molecular and cellular elements that regulate cerebral 
blood flow, blood brain function and the microvascular endothelium. Perturbations of these interconnections promote 
cerebral hypoperfusion, blood brain barrier damage and endothelial dysfunction, with consequent neurodegeneration 
and clinical manifestations of cognitive decline and vascular dementia. To date there are still no therapies to target the 
microvascular endothelium and hence management of these patients remains sub-optimal. 
 
b) White matter, inflammation and hypoxia  
Demyelinating lesions in the CNS white matter are a feature common to both small vessel disease (SVD) and multiple 
sclerosis (MS).  MS has been studied in much greater detail than SVD, raising the possibility that knowledge gained in 
MS may help in understanding the demyelination in SVD.  Demyelinating MS lesions have been classified into four 
types depending on their morphological features during lesion development [62].  Two types, Patterns I and II, have 
morphological features consistent with an autoimmune aetiology, but a third type, Pattern III, has features suggesting 
an important role for tissue hypoxia, based on the similarity with demyelination in the penumbra around ischaemic 
foci.  Since demyelination in SVD is likely to involve tissue hypoxia, it may be instructive to consider the factors 
determining the formation of Pattern III lesions in MS.   
Our understanding of Pattern III demyelination has been greatly advanced by the introduction of a model lesion 
formed in the rodent spinal white matter by the direct intraspinal injection of the pro-inflammatory agent 
lipopolysaccharide (LPS) [63].  The lesion has been validated as an accurate model for Pattern III lesions in MS [62], 
and it results from innate, rather than autoimmune, mechanisms [65].  A surprising feature of the experimental Pattern 
III lesion is its location, because it does not form precisely at the site of injection (in this case in the middle of the 
dorsal columns), as is usual for demyelinating agents, [66,67] but rather it forms near the base of the dorsal columns, 
and after a delay of 7-10 days from the time of injection [68].  It is as if the LPS does not directly cause the 
demyelination, but rather sets in motion a train of events that culminates in the lesion forming at a nearby site.  This 
peculiarity focusses attention on the features at the base of the dorsal columns that make it vulnerable, and these 
include a paucity of blood vessels, and location at a watershed between three arterial trees formed by long, fine, end 
arteries.  All these features render the site particularly vulnerable to hypoxia, especially if the blood supply is impaired.  
The hypoxia kills the most vulnerable cells first, and these include the oligodendrocytes, resulting in the demyelination 
observed.  The suspected key role of tissue hypoxia in causing Pattern III demyelination has been confirmed by the 
observation that breathing raised oxygen avoids tissue hypoxia, and prevents the demyelination [68].   
In summary, impaired vascular perfusion, as occurs in cerebral SVD and MS, appears to cause tissue hypoxia that is 
most severe at sites rendered vulnerable by the vascular architecture, notably at poorly vascularised sites located at 
vascular watersheds, such as those in the periventricular white matter.  The most vulnerable cells, oligodendrocytes, 
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die first, resulting in demyelination, but the tissue can be protected from demyelination, in rodents, if hypoxia is 
avoided by breathing air enriched with oxygen.   
 
c) Microvascular extracellular matrix and small vessels diseases of the brain.  
The extracellular matrix (ECM) of cerebral blood vessels, and especially the basement membrane, is a key 
component of the NGVU that occupies a very strategic location, at the interface between the cerebral microcirculation 
and astrocytes [35]. Proteins constituting or associated with the ECM, referred to as “the matrisome”, have not only 
structural but also biochemical and signaling roles [69]. Hence, any change in the microvascular matrisome could 
have profound impact on the brain parenchyma.  A common feature in both monogenic and sporadic forms of SVDs of 
the brain is the presence of major remodeling of the brain microvascular ECM, with prominent fibrosis, associated with 
severe degeneration of vascular smooth muscle cells [35]. Over the past ten years, genetic studies have revealed that 
most monogenic forms of SVDs are caused by mutations in genes encoding matrisome proteins, namely dominant 
mutations in the coding region of 1 (COL4A1) or 2 (COL4A2) chains of collagen type IV, a major component of 
vascular basement membranes, in COL4A1/COL4A2-related hemorrhagic stroke [70,71], dominant gain-of-function 
mutations in the 3’UTR of COL4A1 in Pontine Autosomal Dominant Microangiopathy with Leukoencephalopathy 
(PADMAL) [72], recessive or dominant loss-of-function mutations in HTRA1, a serine protease regulating the TGFß 
pathway, in Cerebral Autosomal Recessive Arteriopathy with Subcortical Infarcts and Leukoencephalopathy 
(CARASIL) and HTRA1-related SVDs respectively [73-75], and dominant mutation in Cathepsin A in Cathepsin A-
related arteriopathy with strokes and leukoencephalopathy (CARASAL) [76]. Moreover, recent work established that 
cerebrovascular manifestations of CADASIL, the most frequent hereditary SVD and the most aggressive 
vasculopapthy, are driven by perturbations of the microvascular matrisome, as a consequence of an abnormal 
accumulation of the extracellular domain of Notch3 receptor [77,78]. Specifically, elevated levels of tissue inhibitor of 
metalloproteinases 3 (TIMP3), an ECM regulator, blunts the activity of the ADAM17/HB-EGF/(ErbB1/ErbB4) pathway 
leading to the upregulation of voltage-gated potassium channels subfamily 1 in cerebral arterial myocytes, thereby 
attenuating myogenic responses in brain arteries and compromising cerebral blood flow regulation in CADASIL [79]. 
Yet, much work remains to be done to understand in detail the mechanisms linking perturbations of the microvascular 
ECM and cerebrovascular manifestations in these hereditary SVDs. Remarkably, these recent findings suggest that 
similar mechanisms may be at work in sporadic SVDs. Therefore, work is needed to characterize the ’prefibrotic/ 
transitional changes’  of the brain microvascular matrisome in response to age or hypertension, two major risk factors 
of sporadic SVDs, and investigate their contribution to disease initiation. Also, with respect to fibrosis of small vessels 
in the brain, major gaps remain in our understanding of the mechanisms initiating the fibrosis response, in identifying 
the molecular and cellular mediators as well as the effector cells, and in understanding the relationship with SMC 
degeneration. Improvement of animal models of SVDs are needed to address these gaps.  
 
 
d) Intramural periarterial drainage pathways  
 
Arteries that supply the brain are vital for cerebral blood flow but they also play a major role in the drainage of 
interstitial fluid (ISF) from the brain. As arteries penetrate the brain from the subarachnoid space, they acquire a layer 
of pia mater that separates the arterial wall from the glia limitans. After injections of particulate and soluble tracers into 
the subarachnoid space, tracers are entering by glymphatic/convective influx within the arterial pial-glial basement 
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membranes of cortical arteries [80]. When soluble fluorescent tracers are injected into the brain parenchyma, they 
rapidly drain out of the brain with ISF along basement membranes in the walls of cerebral capillaries and basement 
membranes surrounding smooth muscle cells of arteries, a process named intramural periarterial drainage (IPAD) 
[81]. Changes in arterial basement membranes related to genotype (apolipoprotein E4), age, or blockage due to 
immune complexes lead to a failure of intramural perivascular drainage pathways [82,83].  A recent study on a canine 
brain using electron microscopy demonstrated that all arterioles are enveloped in one complete layer of 
leptomeningeal cells, often with a second incomplete layer in the white matter, whereas venules in the white matter 
only occasionally possessed one layer only of leptomeningeal cells [84]. It is possible that dilated perivascular spaces 
observed in the white matter are created between the two adventitial layers of pia mater as a result of the blocked 
drainage pathways in the overlying grey matter [85]. The extensive fibrosis and hyaline change seen in small vessel 
disease disrupts not only the basement membrane pathways carrying ISF out of the brain parenchyma but is also 
likely to contribute to the stiffening of the artery walls that would also impair drainage of ISF from cerebral white 
matter. Clarifying the key factors involved in the impairment of perivascular drainage of ISF such as the role of 
vascular smooth muscle cells and modulators of extracellular matrix are essential therapeutic strategies. It is currently 
unknown whether there is a pattern of anatomical or topographical changes in the cerebrovascular basement 
membrane and perivascular compartment architecture in brains susceptible to different degrees or subtypes of 
vascular dementia. 
 
e) The glymphatic fluid transport system (and interactions with amyloid) 
 
Lymphatic circulation is essential in peripheral organs for the removal of excess fluid and metabolic waste products; 
but the brain, in spite of having the highest metabolic activity of all tissues, has no conventional lymphatic system. A 
fundamentally novel pathway for fluid transport has recently been identified: the glymphatic system consisting of a 
periarterial cerebrospinal fluid (CSF) influx path and a perivenous interstitial fluid (ISF) clearance route, which are 
coupled through convective interstitial bulk flow supported by astrocytic AQP4 water channels [86]. It is designated  
the “glymphatic system” because it operates analogously to the peripheral lymphatic system and the CSF/ISF fluxes 
depend on astroglial AQP4 channels [87] . This brain-wide pathway serves as a waste disposal system of fluid, as 
well as larger solutes and proteins, such as amyloid and tau, from the CNS. Recent work has extended the glymphatic 
concept to show that outflow occurs along both cervical and meningeal/pial lymphatic vessels [88,89] . An interesting 
observation is that the sleep-wake cycle regulates glymphatic activity, which is primarily active during sleep, or the use 
of some anesthesthetic agents [90] .Glymphatic drainage is similar to lymphatic depending upon position, and the 
lateral and supine positions, which are the most popular sleep positions among human and most animal species, 
appear to be superior for amyloid-beta clearance compared with the prone position [91]. Ageing is linked to a sharp 
decline in glymphatic activity in wildtype mice [92]. Moreover, APP/PS1 mice – a murine model of AD exhibited 
reduced glymphatic activity in young mice without amyloid plaques as well as in older mice with plaques. Mice with 
multiple mini-strokes induced by intracarotid injection of cholesterol crystals similarly showed a global decrease in 
glymphatic function [93]. Also, traumatic brain injury triggered a sustained suppression of glymphatic activity [94], 
whereas middle-aged rats with diabetes exhibit increased influx, but reduced clearance, of contrast agents in an MRI 
study [95]. The latter observation can best be explained by trapping of the contrast agent within the neuropil due to 
pathological changes in the extracellular matrix and reactive gliosis, since the volume of fluid influx and efflux must 
match each other. Very recent small studies, one with Gadolinium injected into the CSF, the other using a novel MR 
technique (MREG), provided interesting evidence for the existence of glymphatic fluid transport in the human brain 
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[96,97]. Altogether, glymphatic function has been shown to be altered in all disease states studied so far.  
 
 
GAPS IN KNOWLEDGE AND REQUIREMENTS TO ADVANCE KNOWLEDGE 
 
Following the focussed lectures the participants assembled in small groups and discussed the gaps in the different 
research areas and opportunities for development which are summarised in Table 1. There were several key themes 
to emerge from the discussion groups which are highlighted. 
 
INSERT TABLE 1 
 
METHODOLOGICAL APPROACHES  
 
a) Modelling the neurogliovascular unit in vitro   
The neurogliovascular unit (NGVU) is arguably the most elementary representative functional unit of the brain and 
specific alterations in the NGVU underpin much of the pathophysiology of cerebrovascular disease. The ideal in-vitro 
model will depend upon the particular use and research question to be addressed. However, to probe disease 
mechanisms, attempts should be made to recapitulate the complex micro-environment of the NGVU, including the key 
cell types and the extracellular matrix. The constituent cells should also display mature properties of the NGVU such 
as the specialisation of endothelial cells to impart effective BBB function, specific transport mechanisms and the 
requisite cell-cell interactions including those that underpin NGVU coupling. NGVU models should be robust, yield 
reproducible results and be scalable if they are to be incorporated into drug screening programs. Current models can 
be broadly divided into easily adopted static compartment models such as Transwell cultures and more sophisticated 
flow models based upon a microfluidic design [98]. The latter have emerged in recognition of the importance of flow 
and shear stress of maintaining NGVU properties.  
More than 80% of drug candidates tested in animal models for stroke, and a large proportion so far of drugs tested for 
AD, have failed in clinical trials. Better in-vitro mimics of human systems might help increase the likelihood of 
successful drug discovery. Notably there have been few trials to date of any drugs for SVD, therefore it would be 
premature to level the same criticism at human microvascular disease. Nonetheless, human stem cell technologies 
offer the opportunity to generate patient specific NGVU unit models for improved drug discovery and personalized 
medicine [99]. Differentiation protocols have been described that would produce all the constituent cells of the NGVU 
[100-102]. However further work is required to demonstrate the reproducibility of these methods and the ideal co-
culture conditions. 
NGVU in vitro models should enable assessment of physiological and pathophysiological mechanisms that would be 
difficult to dissect in vivo. Molecular 'omics' technologies in particular provide a means to evaluate disease processes 
in an unbiased approach and identify new drug targets. However, molecular studies require careful planning as they 
can be subject to significant technical confounds and non-relevant biological processes which are only beginning to be 
fully understood. Conducting studies with sufficient samples to allow data normalisation methods and remove 
nuisance variance is important.  Single cell 'omics' are also a powerful technique to deal with heterogeneity in cell 
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culture models as well as reveal cell-specific disease processes. These recent advances in tissue engineering, stem 
cell methods and novel 'omics' platforms are anticipated to enable unprecedented mechanistic insights into NGVU 
brain disorders such as dementia [103].          
 
b) Measuring behavioural outcomes in animal models   
 
In human studies, different cognitive domains can be assessed with a battery of visual touchscreen-based 
tasks using similar stimuli and responses, thus facilitating between-task comparison and potentially reducing 
confounds [104-106]. Conversely, in the rodent, comprehensive cognitive batteries are seldom employed, and 
different cognitive domains are assessed by tasks that typically vary widely in the nature of stimuli, responses, 
reinforcers, and testing environment. Moreover, these tasks often bear no resemblance to the tests used with 
humans. Finally, the measurement of rodent behaviour is notoriously variable across labs and experimenters [107]. 
These factors reduce the likelihood of rodent and human studies assessing consistent and comparable cognitive 
functions, thus compromising the efficacy of translation. There is a recognised need to share standardised operating 
procedures for common outcomes and to improve translation...  
 
One approach to addressing these issues is by using a touchscreen-based cognitive testing method for 
rodents, which has the potential to achieve more accurate, efficient, and reproducible phenotyping of rodents, and 
help bridge the translational divide between animal and human studies of cognition. This method uses an automated 
operant chamber with a computer monitor for the presentation of visual stimuli and an infrared touchscreen assembly 
to record the animal’s responses. The apparatus allows for the flexible presentation of visual stimuli at any location on 
the screen. Rats or mice respond directly to the stimuli by breaking the infrared beams overlaying the touchscreen 
with their nose. Appetitive reinforcers such as strawberry milkshake are delivered in a reward magazine to the rear of 
the chamber.  
 
An extensive battery of tests using this touchscreen cognitive testing apparatus has been developed and 
validated.  The tasks closely parallel human tests and have high translational face validity. Although face validity does 
not guarantee translational neurocognitive validity (i.e., the same cognitive constructs and circuits mediating the tasks 
across species), minimizing methodological differences enables back- and forward-translational opportunities and 
improves the likelihood of neurocognitive validity of touchscreen tasks [108-111]. Touchscreen-based tests now form 
a core component of recommended cognitive test batteries for models of schizophrenia (e.g., NEWMEDS and 
CNTRICS) and AD (e.g., PHARMACOG). The system is presented as a key method in the standard guide to 
behavioural testing for mouse researchers [112], and protocols for an extensive battery of tests have been published 
[113-115]. 
 
c) Experimental Design     
 
Findings from in vivo research may be less reliable if those studies do not adopt and report measures to reduce the 
risk of bias in the experiments reported. The experimental stroke community have been at the forefront of 
implementing changes to improve the conduct and reporting of studies, but the recent impact of these efforts is not 
clear. A systematic identification of recent literature was conducted describing animal experiments inducing middle 
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cerebral artery occlusion or lacunar stroke, and text mining approaches developed automatically to ascertain risk of 
bias reporting from full text articles [116]. There were substantial improvements in the reporting of middle cerebral 
artery occlusion studies since the first systematic report in 2007 [117]. However, in reports of experiments in lacunar 
stroke there was no substantial improvement since the first systematic report of the field to 2012 [118]. This may in 
part reflect that there has been less work on SVD models. The accuracy (true positive plus true negative as a 
percentage of the total) of automated risk of bias annotation ranged from 67% (randomisation, lacunar stroke) to 
100% (sample size calculation, middle cerebral artery occlusion). There therefore remains substantial opportunity for 
improvement in the reporting, and probably the conduct, of animal research modelling stroke, particularly lacunar 
stroke. Automated tools are sufficiently accurate to identify whether studies report the blinded assessment of 
outcome, but improvements are required in the tools to ascertain whether randomisation and a sample size 
calculation were reported. 
 
d) Multi-centre pre-clinical  studies 
There are many steps in the translational pathway from original mechanistic discoveries through to successful 
translation of a therapy to the clinic.  Progress in this pathway has been poor across a range of CNS diseases despite 
increased knowledge of the mechanistic basis of diseases, identification of drug targets and positive drug studies 
using in vitro and in vivo models.  This failure to translate led to criticism of the quality of in vivo drug study design and 
reporting, and the publication and uptake of guidelines (e.g. STAIR, ARRIVE, RIGOR, IMPROVE) [119-123] to 
improve the translational potential of pre-clinical studies.  However, single centre studies, although useful for proof of 
concept of a particular therapy, are unlikely to be rigorous enough to predict the therapies which will also be effective 
in man.   What is needed is an additional step in the pathway where promising therapies which demonstrate efficacy 
in a number of single centre studies are then tested more rigorously on a multi-site platform. Multi-PART (Multicentre 
Preclinical Animal Research Team, http://www.dcn.ed.ac.uk/multipart/) is such a platform, set up with funding from EU 
FP7 for ischaemic stroke.  However, the structure of the platform could easily be adapted for multi-site studies for any 
CNS disease.     
The key objective of Multi-PART was “to implement and establish a platform for international multicentre preclinical 
stroke trials using the repertoire of randomised clinical trial design and the complexities of a multicentre, multimodel 
paradigm”.  This was made possible by the experience within the Multi-PART team of scientists and clinicians  with 
expertise in a range of stroke models and outcome measures, regulation and ethics of in vivo research, precision, 
reproducibility & external validity in animal research,  design and running of clinical trials, statistics, database and web 
site management, good laboratory practice (GLP), and standard operating procedures (SOPs), development & costing  
structures etc. The design of the Multi-PART platform also benefitted from improvements in clinical trial design by 
incorporating strategies to minimize bias, biostatistical advances, data monitoring and auditing, etc.     
Multicentre pre-clinical randomised control trials (pRCTs) in models relevant to SVD and VCI could be performed 
after single centre laboratory studies and a systematic review of all existing data, prior to clinical testing. The need 
for pRCTs reflects the repeated failure of translation from preclinical to clinical development and lack of 
reproducibility between laboratories. Since new healthcare interventions require one or more positive large 
multicentre clinical RCTs prior to introduction, pRCTs should largely follow the design of phase III clinical RCTs 
involving randomisation, treatment and outcome blinding [124-126]. Coordination would need a Trial Steering 
Committee and central database for management of randomisation and data storage. Outcomes would need 
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central adjudication of imaging (e.g. MRI, histology for lesion volume, microbleeds) and videos (behavioural & 
functional testing). Studies can utilise advanced trial techniques such as adaptive design, randomisation, and 
statistical analysis, and the concept extended to designing observational and characterisation studies across 
multiple laboratories. 
Key differences exist between preclinical and clinical RCTs, many of which could be ameliorated by adopting specific 
design elements in preclinical RCTs. Since patients are very heterogeneous, a variety of SVD models would be 
needed. Preclinical RCTs may need to incorporate both positive and neutral control comparator groups. Classically, 
trials have a single primary outcome but co-primary outcomes, composite outcomes, or statistical integration of 
several outcomes are alternatives that may be preferred. The Data Monitoring Committee will assess futility during the 
course of the study with the aim of stopping further development if data are not positive, thus preventing the need for 
further preclinical and clinical testing, and their considerable expense. Conversely, a positive multicentre pRCT will 
considerably enhance the justification for proceeding to clinical development. 
Changing the views of industry, funding agencies and grant reviewers may be necessary to overcome perceptions 
that pRCTs are incremental and not novel or ground-breaking. For large pRCTs, authorship should be discussed prior 
to commencing studies and presents a potential issue for many basic science academics where decisions on hiring, 
promotion and returns on the research excellence framework (REF) are taken on publications and author position.   
 
e) Biomarkers  
Biomarkers can give insights into pathogenesis and suggest potential drug-able targets.  They can inform prognosis 
and be used to ‘enrich’ trial populations with participants who are most likely to have outcomes of interest such as 
progression to dementia.  Biomarkers can be used as surrogate outcome measures for phase II intervention trials, to 
screen treatment prior to large and expensive definitive phase 3 trials.  Finally, biomarkers can be used for 
diagnostics.  In this regard researchers were mindful of the continued debate around the value of biomarkers in 
diagnosis of Alzheimer’s disease (AD) [127,128].  The necessary properties and performance characteristics of a 
biomarker will vary with the proposed purpose. 
MRI modalities were regarded as offering the greatest utility as SVD biomarkers.  A number of different MRI markers 
of SVD may represent useful markers of disease including recent small subcortical infarcts, lacunes, white matter 
hyperintensities, brain volume, and white matter ultrastructure estimated on diffusion tensor imaging (DTI) or other 
quantitative methods [129,130]. Increasingly sophisticated approaches to MRI are moving beyond gross anatomy to 
assess function and connectivity using approaches such as network analysis and these show promise in the mouse 
pre-clinical hypoperfusion model to predict outcome [131] but need further evaluation in prospective patient cohorts 
[132]. Computerised Tomography (CT) has value, particularly as it is routinely available but lacks sensitivity to early 
SVD change.  For imaging, there is no suitable SVD target for radiolabelling that is analogous to amyloid imaging 
although PET approaches may be useful to assess parts of the pathophysiological process such as 
neuroinflammation.  For tissue based markers, use of cerebrospinal fluid (CSF) is under-researched in SVD in direct 
contrast to its importance in AD.  However, the dynamics of the exchange between the peptides in the interstitial fluid 
of the brain and the CSF and their routes in the perivascular compartment still require investigation.  To date no blood 
based biomarker has shown utility, although with ‘omics’ based technologies new markers may be 
discovered.  Electroencephalogram (EEG) has a role in certain neurodegenerative diseases but has limited 
application in SVD.   
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External validation, replication and standardisation of putative biomarkers is critical particularly for multicentre 
work.  At present there is no SVD biomarker suitable for clinical use.  Future trials and observational cohorts should 
create biobanks of tissue (blood, CSF) and imaging data that can be interrogated to validate existing biomarkers or 
discover potential new markers. If biomarkers are to be used as reliable surrogate markers in clinical trials, they must 
fulfil the following criteria: (1) they must be able to predict clinical outcome, as changes induced by a therapy on a 
surrogate marker are expected to reflect changes in a clinically meaningful end point; (2) change in a surrogate 
marker must be detectable prospectively; and (3) the sample size required to show therapeutic efficacy should be 
feasible in the setting of a clinical trial  [133].     
 
f) Sharing, model exchange and potential tissue banks    
 
There is a growing need to address standardisation across models, as far as this is possible. This could include 
standardised protocols for surgery, behavioural testing and clearly defined genetic details in relation to models. 
Central facilities for provision of genetically modified mice would reduce the genetic drift inherent in many of the 
frequently used models. However, their utility is dependent on phenotypes. Human tissue banks are well established 
and provide a useful source of translational material. The development of a tissue bank for preclinical models may be 
a useful resource which could range from cut sections of tissues through to whole organs with standardisation of 
pathological approaches. Potential issues in relation to animal licensing (eg UK Home office) is acknowledged. Tissue 
banks may facilitate validation of published work in a low cost way, by providing tissues prepared by one published 
group for laboratory studies to be undertaken by a second group in a remote laboratory. An open access resource 
where data could be deposited would be particularly useful for negative studies that may not otherwise be published.  
 
 
INDUSTRY PERSPECTIVE ON THE WORKSHOP   
 
Independent of the shape of future research efforts there are a number of critical areas that need to be kept in 
mind that will help facilitate drug discovery and reduce the overall level of risk.  Firstly, the generation of high quality 
targets/ pathways with strong supporting neuropathological, genetic, and/ or epidemiological data.  This will require 
the generation and interrogation of well characterised cohorts, using best practices for data generation and sharing 
that can be found in other pre-competitive settings; these cohorts will be additionally important for longitudinal tracking 
of disease and the identification of potential biomarkers that can be used to make early Go/NoGo decisions within 
drug development programs.   
Secondly, there should be a strong focus on generating a robust translational pharmacology package to 
bridge between preclinical models and clinical development.  A number of basic principles underpin this area: 
understand the temporal expression of target in both the model and the human disease; match the preclinical 
intervention paradigm to the intended therapeutic intent in the clinic (i.e. prevention versus treatment); demonstrate in 
preclinical studies drug exposure at the site of action/ target engagement, expression of downstream target 
pharmacology and importantly generate exposure- response relationships (e.g. EC50 values).   
Finally, as far as possible standardise procedures/ protocols to reduce variability and improve reproducibility 
of preclinical studies.  With this in mind the emergence of the EU-funded MultiPART initiative provides a network 
capability for the conduct of randomised preclinical studies in experimental models relevant to SVD.  Together these 
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approaches will all serve to “de-risk” clinical development and encourage further industry and academic investment in 
SVD research in dementia and stroke.   
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